RGLS up +2.36% percent right now. $RGLS High is at
Post# of 72711
Posted On: 11/10/2014 3:59:30 PM
RGLS up +2.36% percent right now. $RGLS High is at 25.60 and the Low 22.01 with current volume of 2,608,990.
Recent News posted below.
RGLS Regulus Therapeutics Inc Recent Headline News
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 106.85 (+0.40), ACHN: 12.92 (+2.81), RGLS: 20.94 (-1.14), ABBV: 63.73 (+2.23)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 20.93 (-1.15)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.71 (+0.51), GILD: 106.85 (+0.40), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.71 (+0.51), GILD: 106.85 (+0.40), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.71 (+0.51), GILD: 106.84 (+0.39), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.71 (+0.51), GILD: 106.84 (+0.39), ACHN: 12.91 (+2.80), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 326.58 (+5.83), ALNY: 99.14 (+3.30), ISIS: 47.19 (+2.60), OGXI: 2.17 (-0.01), TEVA: 58.04 (+0.34), RGLS: 20.93 (-1.15), GSK: 45.15 (+0.24), SNY: 46.29 (+0.60)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 20.93 (-1.15)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.79 (-0.09), RGLS: 20.93 (-1.15), WAB: 89.48 (+0.21)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?
Recent News posted below.
RGLS Regulus Therapeutics Inc Recent Headline News
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 106.85 (+0.40), ACHN: 12.92 (+2.81), RGLS: 20.94 (-1.14), ABBV: 63.73 (+2.23)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 20.93 (-1.15)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.71 (+0.51), GILD: 106.85 (+0.40), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.71 (+0.51), GILD: 106.85 (+0.40), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.71 (+0.51), GILD: 106.84 (+0.39), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.71 (+0.51), GILD: 106.84 (+0.39), ACHN: 12.91 (+2.80), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 326.58 (+5.83), ALNY: 99.14 (+3.30), ISIS: 47.19 (+2.60), OGXI: 2.17 (-0.01), TEVA: 58.04 (+0.34), RGLS: 20.93 (-1.15), GSK: 45.15 (+0.24), SNY: 46.29 (+0.60)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 20.93 (-1.15)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.79 (-0.09), RGLS: 20.93 (-1.15), WAB: 89.48 (+0.21)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?
(0)
(0)Scroll down for more posts ▼